Table of contents

Expand All Topics

Glanzmann's thrombasthenia

Guidelines

Key sources

The following summarized guidelines for the management of Glanzmann's thrombasthenia are prepared by our editorial team based on guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC 2023), the British Committee for Standards In Haematology (BCSH 2017), and the UK Haemophilia Centre Doctors Organization (UKHCDO/RCOG 2017).
1
2
3

Medical management

Recombinant factor VIIa: as per BCSH 2017 guidelines, consider administering recombinant factor VIIa for first-line treatment or prevention of bleeding in patients with Glanzmann's thrombasthenia.
C
Create free account

Therapeutic procedures

Platelet transfusion: as per BCSH 2017 guidelines, consider administering platelet transfusion (human leucocyte antigen-matched) in patients with Glanzmann's thrombasthenia if pharmaceutical therapies are contraindicated, ineffective, or there is a high risk of bleeding.
C
Create free account

Perioperative care

Perioperative recombinant factor VIIa: as per ESAIC 2023 guidelines, consider administering recombinant factor VIIa in patients with Glanzmann's thrombasthenia undergoing surgery.
C
Create free account

Specific circumstances

Pregnant patients: as per RCOG/UKHCDO 2017 guidelines, develop a careful management plan for patients with Glanzmann's thrombasthenia preparing for labor and delivery, as Glanzmann's thrombasthenia is associated with significant risk of intrapartum and postpartum hemorrhage.
B
Show 11 more
Create free account